2008
RISK FACTORS FOR ANTIBODY MEDIATED REJECTION (AMR) IN KIDNEY TRANSPLANT (KTX) RECIPIENTS WITH POSITIVE CDC B-CELL / FLOW CYTOMETRY CROSSMATCH (CXM) TREATED WITH LOE DOSE INTRAVENOUS IMMUNOGLOBULIN (IVIG) AND RATG THERAPY
Moss A, Heilman R, Chakkera H, Mazur M, Petrides S, Wosniak E, Mekeel K, Mulligan D, Reddy K. RISK FACTORS FOR ANTIBODY MEDIATED REJECTION (AMR) IN KIDNEY TRANSPLANT (KTX) RECIPIENTS WITH POSITIVE CDC B-CELL / FLOW CYTOMETRY CROSSMATCH (CXM) TREATED WITH LOE DOSE INTRAVENOUS IMMUNOGLOBULIN (IVIG) AND RATG THERAPY. Transplantation 2008, 86: 591-592. DOI: 10.1097/01.tp.0000330970.94094.7a.Peer-Reviewed Original Research
2006
THE INFLUENCE OF DONOR-SPECIFIC ANTIBODIES IN KIDNEY TRANSPLANT RECIPIENTS WITH POSITIVE CDC B-CELL/FLOW CYTOMETRY CROSSMATCH TREATED WITH LOW DOSE INTRAVENOUS IMMUNOGLOBULIN AND ANTI-THYMOCYTE GLOBULIN INDUCTION THERAPY.
Moss A, Heilman R, Mazur M, Chakkera H, Wozniak E, Post D, Mulligan D, Reddy K. THE INFLUENCE OF DONOR-SPECIFIC ANTIBODIES IN KIDNEY TRANSPLANT RECIPIENTS WITH POSITIVE CDC B-CELL/FLOW CYTOMETRY CROSSMATCH TREATED WITH LOW DOSE INTRAVENOUS IMMUNOGLOBULIN AND ANTI-THYMOCYTE GLOBULIN INDUCTION THERAPY. Transplantation 2006, 82: 292. DOI: 10.1097/00007890-200607152-00679.Peer-Reviewed Original ResearchAnti-thymocyte globulin induction therapyLow-dose intravenous immunoglobulinDose intravenous immunoglobulinFlow cytometry crossmatchDonor-specific antibodiesKidney transplant recipientsCytometry crossmatchInduction therapyIntravenous immunoglobulinTransplant recipientsCrossmatchTherapyImmunoglobulinRecipientsAntibodies
1995
Monitoring of allograft recipients for the development of HLA‐specific antibodies: Elimination of OKT3 as a complicating factor
Mulligan D, Gentry L, Dombrausky L, Klintmalm G, Nikaein A. Monitoring of allograft recipients for the development of HLA‐specific antibodies: Elimination of OKT3 as a complicating factor. Clinical Transplantation 1995, 9: 438-441. PMID: 8645885, DOI: 10.1111/j.1399-0012.1995.tb00363.x.Peer-Reviewed Original ResearchConceptsOKT3 MoAbPatient seraPanel reactive antibody (PRA) assayPositive reactivityAnti-HLA antibodiesHLA-specific antibodiesOKT3 monoclonal antibodyFalse-positive reactivityMismanagement of patientsAllograft recipientsHumoral rejectionTransplant recipientsAntibody assaysRabbit antimouse immunoglobulinAntibody developmentMonoclonal antibodiesMoAbSerumAntibodiesAntimouse immunoglobulinRecipientsComplicating factorsOKT3PatientsImmunoglobulin